Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...
Analysts are intrested in these 5 stocks: ( ($VRT) ), ( ($AFRM) ), ( ($SRPT) ), ( ($MU) ) and ( ($PEP) ). Here is a breakdown of their recent ...
With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...
Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...
Zacks Investment Research on MSN
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 26.4% in that time frame, outperforming the S&P 500. But investors have to be ...
SOMERSET, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, ...
Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback